Author:
De Colli Marianna,Zara Susi,di Giacomo Viviana,Patruno Antonia,Marconi Guya Diletta,Gallorini Marialucia,Zizzari Vincenzo Luca,Tetè Giulia,Cataldi Amelia
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A (2005) Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 136:1669–74
2. Hillner BE, Ingle JN, Chlebowski RT et al. (2004) American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042–57. Erratum in: J Clin Oncol 2004; 22: 1351
3. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–87
4. Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–51
5. Major P (2002) The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7:481–91
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献